Repaglinide Krka | European Medicines Agency (EMA)

[ad_1]

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Repaglinide Krka is a medicine that contains the active substance repaglinide. It is available as round tablets (white: 0.5 mg; yellow: 1 mg; pink: 2 mg).

Repaglinide Krka is a ‘generic medicine’. This means that Repaglinide Krka is similar to a ‘reference medicine’ already authorised in the European Union (EU) called NovoNorm.

Repaglinide Krka is used in patients who have type-2 diabetes (non-insulin-dependent diabetes). It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.

The medicine can only be obtained with a prescription.

Repaglinide Krka is taken before meals, normally up to 15 minutes before each main meal. The dose is adjusted to give the best control. A doctor should regularly test the patient’s blood glucose to find the lowest effective dose. Repaglinide Krka can also be used for type-2-diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.

The recommended starting dose is 0.5 mg. This dose may need to be increased after one or two weeks.

If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.

Repaglinide Krka is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. Repaglinide Krka helps the pancreas to produce more insulin at mealtimes and is used to control type-2 diabetes.

Because Repaglinide Krka is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Repaglinide Krka is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine’s.

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Repaglinide Krka has been shown to have comparable quality and to be bioequivalent to NovoNorm. Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk. The Committee recommended that Repaglinide Krka be given marketing authorisation.

The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Krka to Krka, d.d., Novo mesto on 4 November 2009.

English (EN)
(43 KB – PDF)

First published: 16/11/2009Last updated: 16/11/2009

View

Product information

English (EN)
(196.87 KB – PDF)

First published: 16/11/2009Last updated: 04/02/2025

View

Latest procedure affecting product information:
N/0000242547

03/02/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(14.01 KB – PDF)

First published: 16/11/2009Last updated: 16/11/2009

View

Product details

Name of medicine: Repaglinide Krka
Active substance: repaglinide
International non-proprietary name (INN) or common name: repaglinide
Therapeutic area (MeSH): Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code: A10BX02

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.

Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

More information on Repaglinide Krka

English (EN)
(66.45 KB – PDF)

First published: 09/07/2007Last updated: 07/12/2012

View

[ad_2]

Source link

Subscribe now

To access premium content

All About Play to Earn With Crypto Games (P2E)

Blockchain Gaming Industry & 5 Crypto Games to Watch

Ethereum Still Leads The Way in Blockchain Gaming

GAIMIN To Introduce NFTs And Play-to-Earn to Minecraft

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead